List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 90 studies with search of: Efavirenz / Emtricitabine / Tenofovir disoproxil fumarate OR Atripla[TREATMENT] AND HIV [CONDITION]
Hide studies that are not seeking new volunteers.
Hide studies with unknown recruitment status.
  Display Options
Rank Status Study
1 Active, not recruiting Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 Versus Efavirenz/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults
Conditions: HIV;   HIV Infections
Interventions: Drug: elvitegravir /emtricitabine /tenofovir DF /GS-9350;   Drug: efavirenz /emtricitabine /tenofovir disoproxil fumarate
2 Active, not recruiting Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults.
Condition: HIV-1 Infection
Interventions: Drug: emtricitabine/rilpivirine/tenofovir disoproxil fumarate;   Drug: efavirenz/emtricitabine/tenofovir disoproxil fumarate
3 Active, not recruiting Study to Evaluate Switching From a Regimen Consisting of a Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) to Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate STR
Condition: HIV-1 Infection
Intervention: Drug: Emtricitabine/rilpivirine/tenofovir DF tablet
4 Active, not recruiting Study of the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 (QUAD) Versus Atripla(R) in HIV Infected, Antiretroviral Treatment-Naive Adults
Conditions: HIV-1 Infection;   HIV Infections
Interventions: Drug: Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350;   Drug: Atripla
5 Recruiting Antiretroviral Therapy (ART) Alone or With Delayed Chemo Versus ART With Immediate Chemo for Limited AIDS-related Kaposi's Sarcoma
Conditions: HIV-1 Infection;   Kaposi's Sarcoma
Interventions: Drug: efavirenz/emtricitabine/tenofovir disoproxil fumarate;   Drug: etoposide
6 Recruiting High Dose Vitamin D and Calcium for Bone Health in Individuals Initiating HAART
Condition: HIV-1 Infection
Interventions: Drug: Atripla;   Drug: Calcium Carbonate;   Drug: Vitamin D3;   Drug: Placebo for calcium carbonate;   Drug: Placebo for vitamin D3
7 Active, not recruiting A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
Condition: Infection, Human Immunodeficiency Virus I
Interventions: Drug: GSK1349572;   Drug: Atripla
8 Recruiting Effect of HAART Vs. Statin Treatment on Endothelial Function and Inflammation/Coagulation
Condition: HIV-1 Infection
Interventions: Drug: Pravastatin sodium;   Drug: Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate
9 Completed ONCE - Only Nocturnal Combination Evaluation of Antiretroviral-Experienced HIV 1 Infected Subjects Switching to Atripla
Condition: HIV Infections
Intervention: Drug: Atripla (ATR) consisting of EFV 600 mg/FTC 200 mg/TDF 300 mg
10 Unknown † Raltegravir + Lopinavir/Ritonavir Versus Efavirenz + Tenofovir + Emtricitabine in Treatment Naive Patients
Condition: HIV Infections
Interventions: Drug: Kaletra + Isentress;   Drug: Atripla
11 Recruiting Treatment of Acute HIV With Emtricitabine, Tenofovir and Efavirenz (CID 0805)
Conditions: Acute HIV Infection;   HIV Infections
Intervention: Drug: Atripla
12 Completed
Has Results 		Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz Versus Combivir/Efavirenz in Antiretroviral-Naive HIV-1 Infected Subjects
Condition: HIV Infections
Interventions: Drug: Emtricitabine (FTC);   Drug: Tenofovir Disoproxil Fumarate (TDF);   Drug: Efavirenz (EFV);   Drug: FTC/TDF;   Drug: FTC/TDF/EFV;   Drug: Lamivudine/zidovudine
13 Completed Evaluation of 4 New Simplified Antiretroviral Treatments in Naive HIV-1 Infected Patients in Africa (ANRS 12115 DAYANA)
Condition: HIV Infections
Interventions: Drug: Tenofovir/Emtricitabine (Truvada) and Nevirapine;   Drug: Tenofovir/Emtricitabine/Efavirenz (Atripla);   Drug: Tenofovir (Viread) and Lopinavir/Ritonavir (Aluvia);   Drug: Tenofovir/Emtricitabine (Truvada) and Zidovudine
14 Active, not recruiting A Pilot Study to Determine if Raltegravir Eradicates HIV From Peripheral Blood Mononuclear Cells
Conditions: HIV Infections;   Acquired Immune Deficiency Syndrome
Interventions: Drug: Raltegravir plus Truvada;   Drug: Atripla
15 Withdrawn Trial of TDF/FTC + Raltegravir Versus TDF/FTC + Efavirenz in HIV-1-Infected Women
Condition: HIV-1 Infections
Interventions: Drug: TDF/FTC Once-Daily + Raltegravir 400 mg Orally Twice-Daily;   Drug: TDF/FTC + Efavirenz (Atripla) Once-Daily
16 Completed ROCKET I - Randomized Open Label Switch for Cholesterol Elevation on Kivexa Evaluation Trial
Condition: HIV Infections
Interventions: Drug: Atripla;   Drug: Kivexa plus Sustiva
17 Completed PK of Tenofovir, Emtricitabine and Efavirenz in Healthy Volunteers
Conditions: HIV Infection;   HIV Infections
Intervention: Drug: Atripla®
18 Recruiting Atripla to Raltegravir Switch Study
Condition: HIV Infection
Intervention: Drug: Truvada/Raltegravir
19 Recruiting Tissue Drug Levels of HIV Medications
Condition: Human Immunodeficiency Virus
Intervention: Drug: Atripla (EFV/TDF/FTC); boosted darunavir & tenofovir/FTC; boosted atazanavir & tenofovir/FTC; raltegravir & tenofovir/FTC
20 Recruiting REMEMBER: Reducing Early Mortality & Morbidity by Empiric Tuberculosis (TB) Treatment
Condition: HIV Infection
Interventions: Drug: Atripla (r);   Drug: Efavirenz;   Drug: Truvada;   Drug: Rifampin/isoniazid/pyrazinamide/ethambutol FDC;   Drug: Rifampin/isoniazid FDC

Previous Page Studies Shown (1-20) Next Page (21-40)
† Indicates status has not been verified in more than two years
Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
RSS Feeds for studies found by your search that were:
  First received in the last 14 days,  
  Last updated (includes received) in the last 30 days
  Download Options




Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services